Evidence map›Paper›PMID 33098134›Full record

ArticleClinical transplantation2020

Impact of Bridging Locoregional Therapies for Hepatocellular Carcinoma on Post-transplant Clinical Outcome.

Nia Adeniji, Vinodhini Arjunan, Vijay Prabhakar, Zeynep Tulu, Neeraja Kambham, Aijaz Ahmed, Paul Kwo, Renumathy Dhanasekaran

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical transplantation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Nia AdenijiStanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0002-7957-5987
Vinodhini ArjunanDivision of Gastroenterology and Hepatology, Stanford University, Stanford, CA, USA.
Vijay PrabhakarDivision of Gastrointestinal and Liver Diseases, Keck School of Medicine of USC, Los Angeles, CA, USA.
Zeynep TuluStanford Hospital and Clinics, Stanford, CA, USA.
Neeraja KambhamDepartment of Pathology, Stanford University, Stanford, CA, USA.
Aijaz AhmedDivision of Gastroenterology and Hepatology, Stanford University, Stanford, CA, USA.
Paul KwoDivision of Gastroenterology and Hepatology, Stanford University, Stanford, CA, USA.
Renumathy DhanasekaranDivision of Gastroenterology and Hepatology, Stanford University, Stanford, CA, USA.ORCID 0000-0001-8819-7511

Funding

Functional Proteomic Analysis and Biomarker Identification in a Novel Mouse Model of Metastatic Hepatocellular Carcinoma (HCC)K08CA222676 · NCI · STANFORD UNIVERSITY · PI DHANASEKARAN, RENUMATHY · 2018 to 2022
$1.0M
NCI NIH HHS K08 CA222676
6 · The paper itself

Abstract

Long waiting times due to ongoing organ shortage have led to increased utilization of locoregional therapies (LRTs) to bridge patients with hepatocellular carcinoma (HCC) to liver transplantation (LT). We performed this study to evaluate the impact of LRTs on post-LT outcomes. We conducted a retrospective study of patients who were transplanted for HCC at Stanford University Hospital between 2008 and 2018 (n = 302). We found that receipt of ≥5 LRTs was an independent and significant predictor of poor overall 5-year survival (58.3% vs. 83.3%; HR 2.26, p = .03), poor recurrence-free 5-year survival (51.9% vs. 80.4%; HR 2.12, p = .03), and was associated with higher rates of recurrence (25.0% vs. 7.4%, p = .001). Moreover, recurrent HCC was more likely to be the cause of death (58.3% vs. 41.7%, p = .04) in patients who received ≥5 LRTs. Also, patients who required ≥5 LRTs showed an overall lower rate of radiological complete response (46.9% vs. 97.8%, p = .001) and were more likely to have more advanced pathological stage tumors in the explant (65.6% vs. 29.6%, p < .001). In conclusion, receipt of ≥5 bridging LRTs prior to LT is associated with worse post-transplant clinical outcomes.

Indexed as

Carcinoma, HepatocellularChemoembolization, TherapeuticLiver NeoplasmsHumansNeoplasm Recurrence, LocalRetrospective StudiesTreatment OutcomeHepatocellular carcinomaLiver cancerLocoregional therapyTransarterial chemoembolizationTransplant

Identifiers

PMID33098134
PMCPMC10367045

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.